Radiopharm Theranostics (ASX: RAD) has announced that the US FDA has granted clearance of its Investigational New Drug application for Betabart (RV-01), its Lu177-B7H3 monoclonal antibody. …
Radiopharm Theranostics receives IND approval to initiate Phase 1 study
July 28, 2025 Australian Biotech
Latest Video
New Stories
-
Alterity Therapeutics reports positive topline data from Phase 2 trial of ATH434
July 28, 2025 - - Australian Biotech -
Radiopharm Theranostics receives IND approval to initiate Phase 1 study
July 28, 2025 - - Australian Biotech -
Clarity successfully completes $203 million institutional placement
July 28, 2025 - - Australian Biotech -
US and EU secure new trade agreement, but 'more to come' on pharmaceuticals
July 28, 2025 - - Latest News -
Leading stakeholders call for urgency on national genomics framework
July 28, 2025 - - Latest News -
Hepatitis Australia wants action as new analysis reveals many still missing cures
July 28, 2025 - - Latest News -
Ok for North Korea to have a say on our health responses, but not the US
July 28, 2025 - - Latest News